- Changing Channels — Fridge-to-Go, Original Singing Bird Clock, Smartdog Jerky and more
- FDA approves revised dosage of HIV-combo drug
- New strength of Intelence gets regulatory approval
- FDA advisory committee recommends PrEP approval for Truvada
- Dr. Reddy's launches generic asthma, allergy, bronchospasm drug
TITUSVILLE, N.J. — The Food and Drug Administration has approved a new strength of a drug for HIV made by Johnson & Johnson, the drug maker said.
J&J subsidiary Janssen Therapeutics announced the approval of an 800-mg formulation of Prezista (darunavir) as a once-daily treatment for HIV. The drug is designed to be taken with food at the same time as ritonavir and in combination with other HIV drugs.
"The single 800-mg tablet provides an option for a reduced pill burden and reflects our ongoing commitment to offer more treatment options for the diverse population of people living with HIV," Janssen Therapeutics medical director Bryan Baugh said.